Scholar Rock initiated with an Overweight at Barclays

Barclays analyst Etzer Darout initiated coverage of Scholar Rock (SRRK) with an Overweight rating and $45 price target The company’s lead asset, apitegromab, is an anti-latent myostatin antibody that has successfully completed a Phase 3 trial in spinal muscular atrophy, and a U.S. FDA approval decision is expected in September 2025, the analyst tells investors in a research note. Scholar Rock’s R&D pipeline also includes SRK-439, an anti-latent myostatin, that the company plans to submit an IND for exploration in rare neuromuscular disorders in the second half of 2025, the firm added.